Intercept (ICPT) Most Lucrative Opportunity Remains in NASH - Baird
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/16/2026
- Chip selloff drags Wall Street lower, offsetting solid earnings, economic data
- TSMC Q2 profit jumps 77% to record, far surpasses expectations
- Oil prices dip but hold near highest in a month on Middle East tensions
- Citi sees Google, Meta and Amazon capex spending at over $800 billion in 2027
- UnitedHealth shares surge on strong earnings beat and guidance
FDA Grants Accelerated Approval to Ocaliva™ (Obeticholic Acid) for the Treatment of Patients with PBC
May 27, 2016 11:42 PM EDTFirst new medicine for PBC in nearly 20 years
Investor conference call Tuesday, May 31 at 8:30 a.m. ET
NEW YORK, May 27, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Ocaliva (obeticholic acid) for the treatment of primary biliary cholangitis, previously known as primary biliary cirrhosis (PBC), in... More
